CMN Weekly (29 August 2025) - Your Weekly CRISPR...
CMN Weekly
Aug. 29, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Jenthera Therapeutics
Company Type: Therapeutics
Main focus: Non-viral delivery of CRISPR-based therapeutics
Company stage: Pre-clinical
Diseases: B-cell lymphoma, small- and non-small cell lung cancer, paediatric B-cell acute lymphoblastic leukaemia
Genome-editing tool: CRISPR-Cas
Funding stage: Seed stage
Location: Saint-Laurent, Canada
Website: https://www.jenthera.com/
Pipeline: https://www.jenthera.com/programs
Partners:
Jenthera Therapeutics is a pre-clinical-stage biotech leveraging its proprietary non-viral delivery technology to develop in vivo CRISPR-based therapeutics. The company's lead internal programme in B-cell lymphoma aims to advance CAR-T therapies, by using its platform’s high frequencies of homology-directed repair to deliver in vivo CAR insertions. The company also has a programme in non-small cell lung cancer. This targets KRAS, a highly prized undruggable oncology target, and represents the first systemically administered ribonucleoprotein CRISPR system achieving targeted delivery to a solid tumour.
